FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022237635> ?p ?o ?g. }

• W2022237635 endingPage "e494" @default.
• W2022237635 startingPage "e494" @default.
• W2022237635 abstract "Vascular involvement is one of the major causes of mortality and morbidity in Behçet disease (BD). There are no controlled studies for the management of vascular BD (VBD), and according to the EULAR recommendations, only immunosuppressive (IS) agents are recommended. In this study, we aimed to investigate the therapeutic approaches chosen by Turkish physicians during the initial event and relapses of VBD and the association of different treatment options with the relapses retrospectively. Patients with BD (n = 936, female/male: 347/589, mean age: 37.6 ± 10.8) classified according to ISG criteria from 15 rheumatology centers in Turkey were included. The demographic data, clinical characteristics of the first vascular event and relapses, treatment protocols, and data about complications were acquired. VBD was observed in 27.7% (n = 260) of the patients during follow-up. In 57.3% of the VBD patients, vascular involvement was the presenting sign of the disease. After the first vascular event, ISs were given to 88.8% and AC treatment to 59.8% of the patients. Median duration of AC treatment was 13 months (1–204) and ISs, 22 months (1–204). Minor hemorrhage related to AC treatment was observed in 7 (4.7%) patients. A second vascular event developed in 32.9% (n = 86) of the patients. The vascular relapse rate was similar between patients taking only ISs and AC plus IS treatments after the first vascular event (29.1% vs 22.4%, P = 0.28) and was significantly higher in group taking only ACs than taking only ISs (91.6% vs 29.1%, P < 0.001). During follow-up, a third vascular event developed in 17 (n = 6.5%) patients. The relapse rate was also similar between the patients taking only ISs and AC plus IS treatments after second vascular event (25.3% vs 20.8%, P = 0.93). When multivariate analysis was performed, development of vascular relapse negatively correlated with only IS treatments. We did not find any additional positive effect of AC treatment used in combination with ISs in the course of vascular involvement in patients with BD. Severe complications related to AC treatment were also not detected. Our results suggest that short duration of IS treatments and compliance issues of treatment are the major problems in VBD associated with vascular relapses during follow-up." @default.
• W2022237635 created "2016-06-24" @default.
• W2022237635 creator A5000849466 @default.
• W2022237635 creator A5014114164 @default.
• W2022237635 creator A5014134418 @default.
• W2022237635 creator A5015504748 @default.
• W2022237635 creator A5016930658 @default.
• W2022237635 creator A5019220311 @default.
• W2022237635 creator A5027358068 @default.
• W2022237635 creator A5029147975 @default.
• W2022237635 creator A5029797000 @default.
• W2022237635 creator A5031190500 @default.
• W2022237635 creator A5032970295 @default.
• W2022237635 creator A5034230946 @default.
• W2022237635 creator A5041518880 @default.
• W2022237635 creator A5043623716 @default.
• W2022237635 creator A5046634445 @default.
• W2022237635 creator A5048184896 @default.
• W2022237635 creator A5048290111 @default.
• W2022237635 creator A5048670551 @default.
• W2022237635 creator A5051443949 @default.
• W2022237635 creator A5053557508 @default.
• W2022237635 creator A5055652128 @default.
• W2022237635 creator A5063531055 @default.
• W2022237635 creator A5067040098 @default.
• W2022237635 creator A5075486603 @default.
• W2022237635 creator A5079571523 @default.
• W2022237635 creator A5084643359 @default.
• W2022237635 creator A5086792048 @default.
• W2022237635 creator A5090987229 @default.
• W2022237635 date "2015-02-01" @default.
• W2022237635 modified "2023-10-18" @default.
• W2022237635 title "Behçet Disease With Vascular Involvement" @default.
• W2022237635 cites W1965841779 @default.
• W2022237635 cites W1991079066 @default.
• W2022237635 cites W2006150593 @default.
• W2022237635 cites W2038870200 @default.
• W2022237635 cites W2053503514 @default.
• W2022237635 cites W2063323018 @default.
• W2022237635 cites W2064081517 @default.
• W2022237635 cites W2143190437 @default.
• W2022237635 cites W2157065994 @default.
• W2022237635 cites W4235673640 @default.
• W2022237635 cites W4254939705 @default.
• W2022237635 doi "https://doi.org/10.1097/md.0000000000000494" @default.
• W2022237635 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4602744" @default.
• W2022237635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25674739" @default.
• W2022237635 hasPublicationYear "2015" @default.
• W2022237635 type Work @default.
• W2022237635 sameAs 2022237635 @default.
• W2022237635 citedByCount "110" @default.
• W2022237635 countsByYear W20222376352015 @default.
• W2022237635 countsByYear W20222376352016 @default.
• W2022237635 countsByYear W20222376352017 @default.
• W2022237635 countsByYear W20222376352018 @default.
• W2022237635 countsByYear W20222376352019 @default.
• W2022237635 countsByYear W20222376352020 @default.
• W2022237635 countsByYear W20222376352021 @default.
• W2022237635 countsByYear W20222376352022 @default.
• W2022237635 countsByYear W20222376352023 @default.
• W2022237635 crossrefType "journal-article" @default.
• W2022237635 hasAuthorship W2022237635A5000849466 @default.
• W2022237635 hasAuthorship W2022237635A5014114164 @default.
• W2022237635 hasAuthorship W2022237635A5014134418 @default.
• W2022237635 hasAuthorship W2022237635A5015504748 @default.
• W2022237635 hasAuthorship W2022237635A5016930658 @default.
• W2022237635 hasAuthorship W2022237635A5019220311 @default.
• W2022237635 hasAuthorship W2022237635A5027358068 @default.
• W2022237635 hasAuthorship W2022237635A5029147975 @default.
• W2022237635 hasAuthorship W2022237635A5029797000 @default.
• W2022237635 hasAuthorship W2022237635A5031190500 @default.
• W2022237635 hasAuthorship W2022237635A5032970295 @default.
• W2022237635 hasAuthorship W2022237635A5034230946 @default.
• W2022237635 hasAuthorship W2022237635A5041518880 @default.
• W2022237635 hasAuthorship W2022237635A5043623716 @default.
• W2022237635 hasAuthorship W2022237635A5046634445 @default.
• W2022237635 hasAuthorship W2022237635A5048184896 @default.
• W2022237635 hasAuthorship W2022237635A5048290111 @default.
• W2022237635 hasAuthorship W2022237635A5048670551 @default.
• W2022237635 hasAuthorship W2022237635A5051443949 @default.
• W2022237635 hasAuthorship W2022237635A5053557508 @default.
• W2022237635 hasAuthorship W2022237635A5055652128 @default.
• W2022237635 hasAuthorship W2022237635A5063531055 @default.
• W2022237635 hasAuthorship W2022237635A5067040098 @default.
• W2022237635 hasAuthorship W2022237635A5075486603 @default.
• W2022237635 hasAuthorship W2022237635A5079571523 @default.
• W2022237635 hasAuthorship W2022237635A5084643359 @default.
• W2022237635 hasAuthorship W2022237635A5086792048 @default.
• W2022237635 hasAuthorship W2022237635A5090987229 @default.
• W2022237635 hasBestOaLocation W20222376351 @default.
• W2022237635 hasConcept C126322002 @default.
• W2022237635 hasConcept C167135981 @default.
• W2022237635 hasConcept C198451711 @default.
• W2022237635 hasConcept C2777466421 @default.
• W2022237635 hasConcept C2779134260 @default.
• W2022237635 hasConcept C2781428731 @default.
• W2022237635 hasConcept C71924100 @default.
• W2022237635 hasConceptScore W2022237635C126322002 @default.

• next